Certara Divests Regulatory & Medical Writing Business for up to $135M to Sharpen Strategic Focus
CERT sits 21% above its 52-week low of $5.19.
Summary
Certara, Inc. is selling its Regulatory and Medical Writing business for up to $135 million, a strategic move to focus on its core Model-Informed Drug Development (MIDD) solutions.
Key Events · M&A and Partnerships · CERT
-
Strategic Divestiture Agreement
Certara entered a definitive agreement to sell its global medical writing and related regulatory services business to Veristat, LLC.
-
Significant Cash Consideration
The transaction includes $100 million in upfront cash, subject to adjustments, and up to $35 million in contingent earn-out payments, totaling up to $135 million.
-
Focus on Core Business
The divestiture is intended to sharpen Certara's strategic focus on its Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions.
-
Material Business Segment Sold
The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, representing a notable portion of the company's operations.
Analysis · CERT · Technology
Certara's agreement to sell its Regulatory and Medical Writing business for up to $135 million represents a significant strategic divestiture. This move aims to sharpen the company's focus on its core Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, aligning with its stated strategy to accelerate AI-integrated modeling and simulation. The transaction provides substantial capital that Certara intends to deploy for long-term value creation, and investors should monitor the updated 2026 guidance for the financial impact of this strategic shift.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CERT was trading at $6.30 on NASDAQ in the Technology sector, with a market capitalization of approximately $950.6M. The 52-week trading range was $5.19 to $15.38. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.